Cagrilintide analogue (Novo Nordisk)

卡瑞林肽类似物 (诺和诺德)

Report date: 2025/01/10 11:50:05
NME

Base Information

Drug NameCagrilintide analogue (Novo Nordisk)
Drug Alias NameNNC0174-1213
ClassificationSmall molecules > Synthetic peptide
Mechanisms of ActionAmylin receptor agonists
TargetsAmylin Receptor
Therapy Area/IndicationsOverweightObesity
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesNovo Nordisk A/S
China Registration ClassN/A

Develop Information

Active CompaniesNovo Nordisk A/S
Inactive CompaniesN/A
Active IndicationsOverweightObesity
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A